The application of a p38 inhibitor can restore GC sensitivity and has been shown in peripheral blood mononuclear and bronchial epithelial cells derived from patients with severe asthma and chronic obstructive pulmonary disease (COPD) [38,39,64]. Here, MAPK1 is linked to chronic obstructive pulmonary disease.